Healthcare / BiotechnologyOslo
$4.41
-0.49 (-10.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-20.7M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$68M
P/E
0.1x
↓EV/EBITDA
N/A
•ROE
-19978.3%
↓Gross Margin
16.8%
↓Debt/Equity
-222.41
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-42.4%
FCF CAGR
—
FCF margin
-608.9%
FCF / Net income
-0.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.3M · net income $97.7M · FCF $-8.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3M | $1.3M | $10.5M | $18.4M | $7.0M |
| Net Income | $97.7M | $97.7M | $-363.4M | $-21.0M | $-18.7M |
| EBITDA | $-5.7M | $-5.7M | $64.5M | $-12.7M | $-14.8M |
| EPS | 38.60 | 38.60 | -267.00 | -34.50 | -45.38 |
| Gross Margin | 16.8% | 16.8% | 33.5% | 54.7% | 33.2% |
| Operating Margin | -892.6% | -892.6% | -340.4% | -159.1% | -295.2% |
| Net Margin | 7297.7% | 7297.7% | -3461.8% | -114.2% | -267.0% |
| Balance Sheet | |||||
| Debt/Equity | -222.41 | -222.41 | -1.73 | 0.61 | 9.09 |
| Current Ratio | 0.03 | 0.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.2M | $-8.2M | $-57.3M | $-20.7M | $-15.4M |
| Returns | |||||
| ROE | -19978.3% | -19978.3% | 337.2% | -24.5% | -1007.0% |
| Valuation | |||||
| P/E | 0.11 | 0.11 | — | — | — |
| EV/EBITDA | — | — | 5.06 | — | — |
| P/B | — | — | — | 1.85 | 81.78 |
| Growth & Yield | |||||
| Revenue Growth | -87.2% | -87.2% | -43.0% | 162.3% | — |
| EPS Growth | 114.5% | 114.5% | -673.9% | 24.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-78.4%
EPS terminal req.
$0.39
Spread vs growth
192.8%
5Y implied EPS CAGR
-58.5%
EPS terminal req.
$0.47
Spread vs growth
173.0%
10Y implied EPS CAGR
-32.5%
EPS terminal req.
$0.76
Spread vs growth
146.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-92.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-267.00 → 38.60
Residual
-92.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.